ANI Pharmaceuticals Inc. (ANIP)

FairStock Score: 64/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn good returns on capital and sell at a sensible price. ANI is a specialty and generic drugmaker, and its filed results show a real turnaround: in fiscal 2025, the year ended 2025-12-31, revenue was $883.4 million and net income was $78.3 million, or $3.32 per diluted share, versus a fiscal 2024 net loss of $18.5 million, or $1.04 per share. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $266.0 million and net income was $24.7 million, or $1.05 per diluted share, up from $211.4 million and $8.5 million in the comparable fiscal Q2 2025 period. That is meaningful growth, though the latest quarter's net income was lower than fiscal Q1 2026's $29.5 million. FairStock calculations put the shares at $70.84 on 2026-10-13 at 15.43 times earnings and 7.36 times EV/EBITDA, with a 10.8% trailing free cash flow yield. Those are not demanding multiples. But the Graham Number is $51.82, implying the price is about 36.7% above that conservative figure, and debt-to-equity is 1.05. Return on equity is 20.46%, but return on capital employed is only 5.45%, so the quality of returns is mixed. Generic and specialty pharma is competitive; ANI's niche products, injectables, and Cortrophin gel help, but I would want durable cash flow and a stronger balance sheet. The Piotroski score of 6/9 and Altman Z-Score of 1.77 suggest improving but not fortress-like financial health. At a FairStock score of 64/100, this is a show-me turnaround, not a wide-moat bargain.

In plain English: ANI Pharmaceuticals makes brand-name and generic medicines. Sales and profits have grown quickly, and the latest quarter showed a solid profit after losses a few years ago. At the current price, the shares look closer to fair or slightly expensive than cheap based on the company's earnings and assets.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer